����ʡ����ҽԺ

��ժҪ�� ���崯��һ�����ص����������Դ��岡�����ֲ����Դ�ͳ���Ƶ���Ч���ѡ��������ٴ��о����֣�����������������������崯���ߵ��ٴ������ʣ��ҿɻ�ó��ڻ��⣬�������ٴ����Ƶİ�ȫ�����ٴ��������Խ����롣����������������������֢���������崯��Ҳ�����������ж�������ͯ���崯����ر�����Ŀǰ���н϶����������������ͬ�������Ƽ������ܼ���ʹ���崯���黺��ı�����������������������ҩ����ٴ������ʣ����ڰ�ȫ�������Ի������ز�����Ӧ��

Lyu Xintong, Zhang Meihua. Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China Corresponding author: Zhang Meihua, Email: zhangmh2004@aliyun.com ��Abstract�� Pemphigus is a serious autoimmune bullous disease, and some cases of pemphigus poorly respond to traditional treatments. In recent years, studies have shown that rituximab could significantly improve recovery rate in pemphigus patients with a long-term remission. Retreatment with rituximab following recurrence also can result in satisfactory clinical remission rates with favorable safety. Rituximab is not only suitable for severe refractory pemphigus, but also for mild, moderate, and even childhood pemphigus. There have been a lot of reports on the control of pemphigus with different therapeutic doses and total doses of rituximab. Rituximab can also be combined to improve clinical remission rate in patients, but drug-related adverse reactions can occur within its safe dose range.